Esami del sangue

Il sangue umano viene prelevato dal paziente e trasferito ad apparecchiature e analizzatori per valutarne la composizione e i fattori che indicano problemi o patologie. Spesso gli esami vengono condotti in un laboratorio di analisi, ma negli ultimi anni, grazie alla miniaturizzazione della tecnologia è possibile spostare l'attrezzatura verso il paziente, con gli analizzatori "portatili" o point of care. La valutazione delle misure effettuate, per derivarne un quadro clinico, viene fatto da un medico specializzato, che ha bisogno di valutare il complesso di più parametri e conoscere elementi essenziali sul paziente, quali l'età, il sesso, l'etnia e l'attuale stato di salute. Il solo confronto con le misure di riferimento (cosiddetti "valori di riferimento") è spesso dannoso e disinformativo.

Prelievo e conservazione
Solitamente il prelievo viene effettuato al mattino per ottenere una migliore standardizzazione e ridurre la variabilità biologica. (fonte: Wikipedia)
Comunicati Stampa

NIFTY™ Becomes First CFDA Approved Non-Invasive Prenatal Genetic Test

On June 30, 2014, the CFDA approved the registration of BGI's BGISEQ-1000 and BGISEQ-100 sequencers, and its prenatal genetic testing kits for NIFTY™ (Non-Invasive Fetal Trisomy test). This is the first genetic test based on next generation sequencing technology to be approved by the CFDA and makes the NIFTY™ test the only certified non-invasive prenatal test currently available in China. (PR Newswire - 07/07/2014) Leggi

Point of Care Diagnostic Testing: World Markets Report 2013

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.Point of Care Diagnostic Testing World Markets 2013 describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the... (PR Newswire - 01/10/2013) Leggi

Inostics' Blood-based Mutation Testing Receives CLIA Certification

"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making. We are extremely excited to be able to bring this solution to cancer patients as OncoBEAM tests offer a significant enhancement to clinical care over traditional tissue-based molecular testing," Dr. Frank Diehl, CSO of Inostics, said. (PR Newswire - 30/05/2013) Leggi

Inostics DNA Blood Test Provides a More Precise Picture of Resistance Mutations Than Traditional Biopsies

Therapies targeted to specific cancer-causing mutations may be the most promising strategy in cancer treatment. However, inter- and intra-tumor heterogeneity pose a significant challenge to maximizing therapeutic efficacy. Within a single patient, different cancer cells may have different sets of mutations making it very difficult to detect all of the relevant mutations in a single tissue biopsy.   (PR Newswire - 09/04/2013) Leggi

New Study Shows Promising Results For Tests That Can Help Doctors Better Evaluate Potential Heart Attacks

Blood tests for troponin—a protein found in the heart muscle—can detect heart muscle injury. The study, "Determination of 19 Cardiac Troponin I and T Assay 99th Percentile Values from a Common Presumably Healthy Population," evaluated 19 cardiac troponin assays in a healthy population of men and women, and included Abbott's high sensitive Troponin-I assay currently under development. (PR Newswire - 13/12/2012) Leggi
1 2